0001415889-24-006079.txt : 20240301
0001415889-24-006079.hdr.sgml : 20240301
20240301161514
ACCESSION NUMBER: 0001415889-24-006079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Berman David M
CENTRAL INDEX KEY: 0001955244
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39992
FILM NUMBER: 24709917
MAIL ADDRESS:
STREET 1: C/O PROVENTION BIO, INC.
STREET 2: 55 BROAD STREET
CITY: RED BANK
STATE: NJ
ZIP: 07701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunocore Holdings plc
CENTRAL INDEX KEY: 0001671927
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 90 PARK DRIVE
STREET 2: MILTON PARK, ABINGDON
CITY: OXFORDSHIRE
STATE: X0
ZIP: OX14 4RY
BUSINESS PHONE: 01235 5430281
MAIL ADDRESS:
STREET 1: 90 PARK DRIVE
STREET 2: MILTON PARK, ABINGDON
CITY: OXFORDSHIRE
STATE: X0
ZIP: OX14 4RY
FORMER COMPANY:
FORMER CONFORMED NAME: Immunocore Ltd
DATE OF NAME CHANGE: 20160412
4
1
form4-03012024_040305.xml
X0508
4
2024-02-28
0001671927
Immunocore Holdings plc
IMCR
0001955244
Berman David M
C/O IMMUNOCORE HOLDINGS PLC
92 PARK DRIVE, MILTON PARK, ABINGDON
OXFORDSHIRE
X0
OX14 4RY
UNITED KINGDOM
false
true
false
false
HEAD OF R&D
1
Ordinary Shares
2024-02-28
4
M
0
36509
17.46
A
36509
D
Ordinary Shares
2024-02-28
4
S
0
16900
67.61
D
19609
D
Ordinary Shares
2024-02-28
4
S
0
7472
68.84
D
12137
D
Ordinary Shares
2024-02-28
4
S
0
10937
69.73
D
1200
D
Ordinary Shares
2024-02-28
4
S
0
1200
70.45
D
0
D
Employee Share Option (Right to Buy)
17.46
2024-02-28
4
M
0
36509
0
D
2028-09-12
Ordinary Shares
36509
271790
D
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.08 to $68.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.26 to $70.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.42 to $70.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Immediately exercisable.
/s/ Lily Hepworth, Attorney-in-Fact
2024-03-01